Chung Christine H, Schwartz David L
Department of Oncology, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB-1 Room 344, Baltimore, MD 21231-1000, USA.
Otolaryngol Clin North Am. 2012 Aug;45(4):795-806. doi: 10.1016/j.otc.2012.04.002. Epub 2012 May 30.
Patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) enjoy better treatment outcomes than patients suffering from HPV-negative head and neck cancer. To maintain the integrity and utility of future clinical trials, HPV-positive SCCOP must be studied as a distinct entity. The discovery of HPV-positive disease has (1) convoluted comparison of current phase II trial data to historical controls, (2) made formal stratification for HPV infection status an imperative for future phase III trial design, and (3) drawn focus toward opportunities for personalization of treatment intensity. This review discusses these research issues.
人乳头瘤病毒（HPV）阳性口咽鳞状细胞癌（SCCOP）患者比HPV阴性头颈癌患者享有更好的治疗效果。为保持未来临床试验的完整性和实用性，HPV阳性SCCOP必须作为一个独特的实体进行研究。HPV阳性疾病的发现已导致：（1）当前II期试验数据与历史对照的比较变得复杂；（2）使HPV感染状态的正式分层成为未来III期试验设计的必要条件；（3）将焦点引向治疗强度个体化的机会。本综述讨论了这些研究问题。
